ACM
Altium Capital Management Portfolio holdings
AUM
$34.4M
This Quarter Return
+27.24%
1 Year Return
-2.5%
3 Year Return
+357.21%
5 Year Return
–
10 Year Return
–
AUM
$195M
AUM Growth
+$195M
(-26%)
Cap. Flow
-$107M
Cap. Flow
% of AUM
-54.62%
Top 10 Holdings %
Top 10 Hldgs %
44.8%
Holding
156
New
23
Increased
14
Reduced
15
Closed
62
Top Buys
| 1 |
Astria Therapeutics
ATXS
|
$13.6M |
| 2 |
Replimune Group
REPL
|
$4.35M |
| 3 |
Tandem Diabetes Care
TNDM
|
$4.05M |
| 4 |
Amylyx Pharmaceuticals
AMLX
|
$3.88M |
| 5 |
Outlook Therapeutics
OTLK
|
$3.59M |
Top Sells
| 1 |
MediWound
MDWD
|
$16.9M |
| 2 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$8.27M |
| 3 |
Insmed
INSM
|
$5.77M |
| 4 |
MBTC
Nocturne Acquisition Corporation Ordinary Shares
MBTC
|
$5.17M |
| 5 |
VRNA
Verona Pharma
VRNA
|
$4.94M |
Sector Composition
| 1 | Healthcare | 89.27% |
| 2 | Financials | 5.84% |
| 3 | Communication Services | 0.42% |
| 4 | Industrials | 0.37% |
| 5 | Materials | 0.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Astria Therapeutics
ATXS
$349M
| $20.2M | 10.26% | 1,355,372 +910,372 | +205% | +$13.6M |
|
2
ADMA Biologics
ADMA
$4.12B
| $11.1M | 5.66% | 2,870,000 -13,710 | -0.5% | -$53.2K |
|
|
KDNY
3
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $10.1M | 5.13% | 385,000 -140,000 | -27% | -$3.67M |
|
|
BLU
4
DELISTED
BELLUS Health Inc.
BLU
| $9.31M | 4.73% | 1,132,000 | – | – |
|
|
PEPL
5
DELISTED
PepperLime Health Acquisition Corporation Class A Ordinary Share
PEPL
| $7.5M | 3.81% | 735,000 | – | – |
|
6
Akero Therapeutics
AKRO
$3.74B
| $6.85M | 3.48% | 125,000 -15,000 | -11% | -$822K |
|
|
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
| $6.43M | 3.27% | 1,025,000 -725,000 | -41% | -$4.55M |
|
|
VRNA
8
Verona Pharma
VRNA
$9.16B
| $5.62M | 2.86% | 215,000 -189,000 | -47% | -$4.94M |
|
|
ITCI
9
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $5.29M | 2.69% | 100,000 | – | – |
|
|
10
Amylyx Pharmaceuticals
AMLX
$836M
| $5.17M | 2.63% | 140,000 +105,000 | +300% | +$3.88M |
|
11
Rhythm Pharmaceuticals
RYTM
$6.85B
| $4.95M | 2.52% | 170,000 | – | – |
|
12
Arcellx
ACLX
$3.85B
| $4.65M | 2.36% | 150,000 +35,000 | +30% | +$1.08M |
|
|
13
Replimune Group
REPL
$422M
| $4.35M | 2.21% | +160,000 | New | +$4.35M |
|
|
KRTX
14
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $4.32M | 2.2% | 22,000 +5,000 | +29% | +$983K |
|
15
Xtant Medical Holdings
XTNT
$83.3M
| $4.12M | 2.1% | 6,246,291 | – | – |
|
|
ISEE
16
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $4.07M | 2.07% | 190,000 +65,000 | +52% | +$1.39M |
|
|
17
Tandem Diabetes Care
TNDM
$845M
| $4.05M | 2.06% | +90,000 | New | +$4.05M |
|
18
Glaukos
GKOS
$5.5B
| $3.97M | 2.02% | 91,000 -6,000 | -6% | -$262K |
|
19
Esperion Therapeutics
ESPR
$448M
| $3.86M | 1.96% | 620,000 -39,869 | -6% | -$248K |
|
|
20
Outlook Therapeutics
OTLK
$37.8M
| $3.59M | 1.83% | +3,327,404 | New | +$3.59M |
|
21
ResMed
RMD
$40.2B
| $3.54M | 1.8% | 17,000 | – | – |
|
|
AKYA
22
DELISTED
Akoya BioSciences
AKYA
| $3.16M | 1.6% | 330,000 +34,000 | +11% | +$325K |
|
23
Quanterix
QTRX
$211M
| $3.11M | 1.58% | 224,800 +129,800 | +137% | +$1.8M |
|
24
Myriad Genetics
MYGN
$593M
| $3.08M | 1.56% | 212,000 +26,000 | +14% | +$377K |
|
25
KORU Medical Systems
KRMD
$195M
| $3.05M | 1.55% | 855,000 -140,500 | -14% | -$502K |
|